GSK Braces For A Hit To Its Vaccines Business Despite A Strong First Quarter
Stay-at-home restrictions due to COVID-19 have started to impact the company's vaccines business, including the big growth driver Shingrix.
You may also be interested in...
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
Results from the first major trial of remdesivir are positive, but fail to show clear mortality benefit - making its forthcoming approval just the first step towards winning the war on COVID-19.